What does PD-L1 positive or negative mean?

被引：263

作者：

Ribas, Antoni ^{[1
,2
]}

Hu-Lieskovan, Siwen ^{[1
,2
]}

机构：

[1] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, JCCC, Los Angeles, CA 90095 USA

来源：

JOURNAL OF EXPERIMENTAL MEDICINE | 2016年 / 213卷 / 13期

基金：

美国国家卫生研究院;

关键词：

CELL LUNG-CANCER; ADAPTIVE IMMUNE RESISTANCE; ADVANCED MELANOMA; UNTREATED MELANOMA; CLINICAL ACTIVITY; HODGKIN LYMPHOMA; OPEN-LABEL; EXPRESSION; BLOCKADE; NIVOLUMAB;

D O I：

10.1084/jem.20161462

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti-PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.

引用

页码：2835 / 2840

页数：6

共 50 条

[1] A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative
Ratcliffe, Marianne J.
Sharpe, Alan
Midha, Anita
Barker, Craig
Scorer, Paul
Walker, Jill
CANCER RESEARCH, 2016, 76
[2] PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?
Moreno-Vicente, Julia
Beers, Stephen A.
Gray, Juliet C.
CANCER LETTERS, 2019, 457 : 74 - 85
[3] Determination of PD-L1 positive CETCs as a biomarker for PD-1/PD-L1 treatment monitoring
Pizon, M.
Schott, D.
Pachmann, U.
Pachmann, K.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 89 - 89
[4] Identifying immune infiltration pattern of PD-L1 positive and negative lung adenocarcinoma
Heidel, C.
Jokic, M.
Faehnrich, A.
Kuempers, C.
Vogel, W.
Vlasic, I.
Kirfel, J.
Busch, H.
Perner, S.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 110 - 111
[5] Macrophages are important source of PD-L1 and PD-L1 expressing in macrophages affect the prognosis of NSCLC patients with tumor PD-L1 negative
Liu, Y.
Cao, L.
Che, X.
Qiu, X.
Li, Z.
Yang, B.
Wang, S.
Qu, X.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 531 - 532
[6] The efficacy of PD-L1 blockade on PD-L1 negative medulloblastoma is dependent on timing and the tumor microenvironment
Allen, Frederick
Dorand, Rodney Dixon
Rauhe, Peter
Petrosiute, Agne
Huang, Alex Y.
JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
[7] What does radiomics do in PD-L1 blockade therapy of NSCLC patients?
Cui, Ruichen
Yang, Zhenyu
Liu, Lunxu
THORACIC CANCER, 2022, 13 (19) : 2669 - 2680
[8] Frequency of PD1-negative and PD-1-positive ILCs in breast cancer patients depending on PD-L1 status
Alifanov, V. V.
Buzenkova, A.
Popova, N. O.
Savelieva, O. E.
Tashireva, L. A.
Perelmuter, V. M.
ANNALS OF ONCOLOGY, 2021, 32 : S858 - S858
[9] Beyond PD-L1: unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumour microenvironment
Miles, J.
Gumuzio, J.
Calleja, V.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S99 - S100
[10] Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment
Gumuzio, Juan
Calleja, Veronique
Miles, James
Sancehz-Magraner, Lissete
Aguirre, Fernando
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)

← 1 2 3 4 5 →